Drug Policies
The Yorkshire and the Humber Specialised Commissioning Group has developed and implemented a number of commissioning policies on behalf of PCTs in the area.
Cancer Drug Policies
The following cancer drug policies have been developed by the Yorkshire and the Humber Specialised Commissioning Group and have been adopted by NHS Wakefield District, to access the full documents please visit the Specialised Commissioning Group Cancer Drug Policies webpage 
.
- Bortezomib for Multiple Myeloma
- Thalidomide for Multiple Myeloma
- Lenalidomide for Multiple Myeloma
- Cetuximab for Head and Neck Cancer
- Cetuximab for First Line Colorectal Cancer
- Bevacizumab, Sorafenib, Sunitinib and Temsirolimus for Renal Cancer
- Rituximab for Chronic Lymphocytic Leukaemia
- Sunitinib for Malignant Gastrointestinal Stromal Tumours
- Pemetrexed for Non Small Cell Lung Cancer
- Cetuximab for Third Line K-ras Wild Type metastatic Colorectal Cancer
- Topotecan for Cervical Cancer
- Topotecan for Lung Cancer
- Bevacizumab for mBC - Metastatic Breast Cancer
- Abraxane for Breast Cancer
- Docetaxel for Head and Neck Cancer
- Everolimus for mRCC - Advanced and/or metastatic renal cell carcinoma
- Trabectedin for Sarcoma
- Gefitinib for NSCLC - Locally advanced or metastatic non-small cell lung cancer
- Sorafenib for hepatocellular carcinoma
- Pemetrexec maintenance for non-small cell lung cancer
- Capecitabine for Gastric Cancer
- Rituximab for relapsed or refractory CLL - chronic lymphocytic leukaemia
- Imatinib for GIST - Unresectable and/or metastatic gastrointestinal stromal tumours
- Bevacizumab for metastatic colorectal cancer
- Cetuximab for 2nd line and subsequent metastatic colorectal cancers
- Gemcitabine IV infusion for pancreatic cancers
Non-Cancer Drug Policies
The following cancer drug policies have been developed by the Yorkshire and the Humber Specialised Commissioning Group and have been adopted by NHS Wakefield District, to access the full documents please visit the Specialised Commissioning Group Non-Cancer Drug Policies webpage .
- Criteria for the Use of Disease Modifying Therapies for MS - Multiple Sclerosis
- Pulmonary Hypertension
- Palivizumab for Respiratory Syncytial Virus
- Rituximab for Rheumatoid Arthritis
- Extavia for MS - Multiple Sclerosis
- Sativex for MS - Multiple Sclerosis
- Antifungals for Chronic Pulmonary Aspergillosis
- Somatropin for Growth Failure in Children
- Armour Thyroid for Hypothyroidism
- Botulinum toxin type A for Hyperhidrosis
- Botulinum toxin type A for Overactive Bladder
- Botulinum toxin type A for Prophyllaxis of Migraine
- Botulinum toxin type A for Anal Fissures
- Co-careldopa for Parkinson's disease
- Inflixamab for Hidradenitis Suppurtiva
- Mecasermin for Growth Failure in Children
- Rituximab for SLE - systemic lupus erythematosus - in Adults
